TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Dilip Shanghvi to continue as the Executive Chairman of the Board
Honeywell Aclar film technology will enable Evertis to develop high-quality barrier packaging solutions
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Subscribe To Our Newsletter & Stay Updated
